Biologic Switch Revs Up Response in Plaque Psoriasis

(MedPage Today) -- NEW ORLEANS -- Plaque psoriasis that responded inadequately to an interleukin (IL)-17 inhibitor often had deep and durable responses after switching to the IL-23 inhibitor risankizumab (Skyrizi), a long-term prospective trial...

Source: MedPage Today Dermatology - March 19, 2023 Category: Dermatology Source Type: news